INT236278

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2008
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 2.16
Pain Relevance 0.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (CADPS) cytosol (CADPS)
CADPS (Homo sapiens)
Pain Link Frequency Relevance Heat
anakinra 42 88.64 High High
antagonist 11 85.16 High High
Inflammation 59 62.88 Quite High
Arthritis 9 48.80 Quite Low
spinal inflammation 1 48.00 Quite Low
psoriasis 3 47.04 Quite Low
Crohn's disease 3 42.80 Quite Low
alcohol 1 40.68 Quite Low
corticosteroid 3 38.08 Quite Low
Pain 7 31.88 Quite Low
Disease Link Frequency Relevance Heat
Syndrome 245 100.00 Very High Very High Very High
Cryopyrin-associated Periodic Syndromes 56 96.04 Very High Very High Very High
Apoptosis 2 91.44 High High
Crystal Associated Disease 8 85.36 High High
Tumor Necrosis Factor Receptor-associated Periodic Syndrome 8 68.80 Quite High
Fever 24 68.40 Quite High
Disease 59 67.80 Quite High
INFLAMMATION 59 62.88 Quite High
Adverse Drug Reaction 4 54.24 Quite High
Immune System Diseases 3 52.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A schematic diagram of the MAPCEL and VACES used to deliver CAPs and filtered air to human subjects is given in Figure 1.
Negative_regulation (deliver) of CAPs
1) Confidence 0.36 Published 2008 Journal Environ Health Perspect Section Body Doc Link PMC2430224 Disease Relevance 0 Pain Relevance 0
In addition to patients who carry recognisable CIAS1 mutations, there are a number of patients in whom such mutations are not present but have clinically apparent CAPS.
Neg (not) Negative_regulation (present) of CAPS associated with syndrome
2) Confidence 0.27 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727888 Disease Relevance 0.96 Pain Relevance 0.03
The results of both of these studies are consistent, with rilonacept inducing a rapid and sustained reduction in the signs and symptoms of CAPS, regardless of the method of assessment.
Negative_regulation (reduction) of CAPS associated with syndrome
3) Confidence 0.27 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727888 Disease Relevance 0.21 Pain Relevance 0
A published phase III clinical study demonstrated that canakinumab was effective in CAPS patients, with 34 of 35 patients achieving a complete clinical response within 15 days [6].
Negative_regulation (effective) of CAPS associated with syndrome
4) Confidence 0.12 Published 2010 Journal F1000 Med Rep Section Body Doc Link PMC2948378 Disease Relevance 0.99 Pain Relevance 0.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox